Collegium to Report First Quarter 2026 Financial Results on May 7, 2026

Rhea-AI Summary

Collegium Pharmaceutical (Nasdaq: COLL) will report first quarter 2026 financial results before the market opens on May 7, 2026. A live conference call and webcast will follow at 8:00 a.m. ET. An audio webcast will be available for replay on the company website about two hours after the event.

News Market Reaction – COLL

-2.36%

-2.36% Session close to close

In the Apr 23 session, COLL declined 2.36%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Collegium’s Q1 2026 earnings release and conference call, c...

Analysis

This announcement sets the timetable for Collegium’s Q1 2026 earnings release and conference call, continuing the pattern established with the February 26, 2026 full-year report. The key takeaway is when management will update the market on performance following recent strategic steps, including the planned AZSTARYS acquisition. Investors may focus on revenue growth, integration progress, and cash flow metrics once results are reported.

Key Figures

Q1 2026 results date: May 7, 2026 Conference call time: 8:00 a.m. ET US dial-in: (877) 407-8037 +1 more

4 metrics

Q1 2026 results date May 7, 2026 Scheduled earnings release before market open

Conference call time 8:00 a.m. ET Q1 2026 earnings call start time

US dial-in (877) 407-8037 Domestic access number for earnings call

International dial-in (201) 689-8037 International access number for earnings call

Previous Earnings date Reports

1 past event · Latest: Feb 12 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 12	Earnings date notice	Neutral	+0.3%	Announced timing and access details for FY25 earnings release and call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date communication prompted a small positive move, suggesting these scheduling updates have historically been low-impact catalysts.

Recent Company History

Over recent months, Collegium has highlighted investor outreach, portfolio expansion, and data visibility. Key items include conferences in March and April 2026, an announced $650 million AZSTARYS acquisition with additional milestones, and ADHD awareness campaigns. Against this backdrop, the latest notice of the Q1 2026 earnings date continues a regular cadence of financial communications similar to the February 26, 2026 FY25 earnings date announcement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

Conference Call Information 
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by JORNAY PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with JORNAY PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com

FAQ

When will Collegium (COLL) report Q1 2026 results and what time is the earnings call?

Collegium will report Q1 2026 results before market open on May 7, 2026. According to the company, a live conference call and webcast will begin at 8:00 a.m. ET the same day for investors and media.

How can investors access the Collegium (COLL) Q1 2026 earnings call and webcast?

Investors can dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the Collegium Q1 2026 Earnings Call. According to the company, an audio webcast is available on the Investors section of the company website.

Will Collegium (COLL) provide a replay of the Q1 2026 webcast and where will it be hosted?

Yes. According to the company, the audio webcast will be posted for replay on the company website approximately two hours after the live event, accessible from the Investors section for on-demand listening.

What should shareholders prepare before attending Collegium (COLL) Q1 2026 earnings call on May 7?

Shareholders should note the May 7, 2026 date and 8:00 a.m. ET start time, and have the conference dial-in or webcast link ready. According to the company, referencing the call title will help ensure access.

Where can I find the press release details for Collegium Pharmaceutical (COLL) Q1 2026 earnings and the webcast link?

The press release and webcast link will be posted in the Investors section of the company website. According to the company, the webcast and replay will be available on www.collegiumpharma.com around the event timing.